A23V 2250/706
Vitamin b12
Official title: Vitamin B12
A23V2250/706 (Vitamin b12) appears on 23 US grants and 36 published applications in this corpus.
Search patents in A23V- Granted patents
- 23
- Published applications
- 36
- Assignees
- 13
- Inventors
- 36
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 4 |
| 2019 | 0 | 9 |
| 2020 | 6 | 4 |
| 2021 | 5 | 2 |
| 2022 | 6 | 5 |
| 2023 | 2 | 3 |
| 2024 | 2 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Nutritional compositions and infant formula for promoting de novo myealination21 Jul 2026US 12,685,331 B2Societe des Produits Nestle S. A.
- Nutritional composition and infant formula for promoting de novo myelination2 Dec 2025US 12,484,608 B2Societe des Produits Nestle S. A.
- Nutritional composition and infant formula for promoting de novo myelination21 May 2024US 11,986,003 B2Societe des Produits Nestle S. A.
- Nutritional composition and infant formula for promoting myelination of the brain19 Mar 2024US 11,930,836 B2Societe des Produits Nestle S. A.
- Deuterated caffeine and uses thereof6 Jun 2023US 11,666,073 B2Lennham Pharmaceuticals, Inc.
- Compositions and their use11 Sep 2025US 2025/0280863 A1Societe des Produits Nestle S. A.
- Deuterated caffeine and uses thereof7 Aug 2025US 2025/0248424 A1Lennham Pharmaceuticals, Inc.
- Nutritional composition and infant formula for promoting de novo myelination24 Oct 2024US 2024/0349771 A1Societe des Produits Nestle S. A.
- Deuterated caffeine and uses thereof29 Aug 2024US 2024/0284942 A1Lannham Pharmaceuticals, Inc,
- Deuterated caffeine and uses thereof23 Nov 2023US 2023/0371555 A1Lennham Pharmaceuticals, Inc.
Most cited
By later US patents
- Vitamin supplement compositions with enhanced bioavailability5US 10,617,700 B12020
- Deuterated caffeine and uses thereof4US 10,582,716 B1Lennham Pharmaceuticals, Inc. · 2020
- Deuterated caffeine and uses thereof3US 10,765,130 B1Lennham Pharmaceuticals, Inc. · 2020
- Nutritional formulations using human milk oligosaccharides for modulating inflammation2US 10,624,916 B2Abbott Laboratories · 2020
- Infant formulas having vitamin complexes with enhanced bioavailability2US 11,122,833 B12021